Cantor Fitzgerald analyst Charles Duncan left investor meetings with Aimmune Therapeutics management with "enhanced conviction" about AR101's approvability and commercial prospects. He believes the regulatory review with the FDA is "now gaining traction." The analyst views 2019 and 2020 as being transformational for Aimmune "as it evolves from being development stage to becoming a fully-integrated commercial stage company." Importantly, the company has sufficient cash to fully fund through the approval and early commercialization in the U.S. and Europe, Duncan tells investors in a research note. He reiterates an Overweight rating on the shares with a $45 price target.